Maybe you heard about it after watching the Samuel L. Jackson movie "Unbreakable." Or maybe after binging Season 11 of "Grey's Anatomy." Or maybe the words "osteogenesis imperfecta," or "OI," don't ...

There are no FDA-approved therapies for the treatment of OI.

Trial results show setrusumab reduces the incidence of fracture and increases bone density and formation. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

Topline data were announced from two phase 3 studies evaluating setrusumab in patients with osteogenesis imperfecta.

A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...

Shares of Ultragenyx Pharmaceutical RARE and Mereo BioPharma MREO plunged 42.3% and 87.6%, respectively, on Dec. 29 after the companies announced disappointing data from the phase III Orbit and Cosmic ...

LONDON and REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of ...

NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE) and Mereo BioPharma Group plc (MREO), today announced that the randomized, placebo-controlled Phase 3 portion of ...

Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction endpoints, eroding its key ...